- Tech & Product DD
- E-Health & MedTech
Code & Co. advises GUS Group ahead of its investment in DORNER Health IT Solutions, a leading provider of modern and integrated laboratory software
Founded over 40 years ago, DORNER has developed into one of the largest specialists for modern laboratory software solutions in the German-speaking region. The company has over 70 employees.
- GUS Group to become the new majority shareholder in DORNER Health IT Solutions.
- GUS Group to provide exceptional network, LIMS expertise, and financial strength to support DORNER’s growth as well as the continued development of existing products and new solutions.
With almost 40 years on the market, DORNER is one of the leading providers of IT for the healthcare sector. Its products optimize processes in clinics and laboratories. The company provides individually adapted and modularly combinable software solutions. As a leading provider of healthcare software solutions, it is in operation at over 9000 workstations.
DORNER also developed the first laboratory information systems (LIS / LIMS) together with the University of Freiburg. It remains state of the art to this day. The company anticipates additional opportunities to develop existing products further and work on entirely new products with the support of GUS Group.
As a process specialist, GUS Group develops, implements, and operates software that fully maps and efficiently controls companies’ processes. As such, GUS has been a sought-after solution partner for the process industry (pharmaceuticals, medical technology, chemicals, cosmetics, food) and for logistics for almost 40 years.
Code & Co. conducted an evaluation of DORNER Health IT Solution ahead of GUS Group’s investment in the company. This Tech & Product Due Diligence investigated development processes, DORNER’s technological infrastructure and architecture, as well as the overall software design. Furthermore, Code & Co. assessed the company’s product growth plans, its use of highly specific flows and processes, and conducted a technical risk assessment.
Bregal Unternehmerkapital (“BU”) is part of a family-owned business that has grown over several generations. The BU funds invest in European mid-sized companies across a wide range of sectors with a focus on market leaders and “hidden champions” with strong management teams and outbreak potential. With patient capital, entrepreneurial expertise, and a partnership approach, our team works closely with entrepreneurs to develop, internationalize and digitalize portfolio companies, and to help them generate sustainable value on a responsible basis.
As part of its comprehensive commitment to ESG, BU also supports existing portfolio companies with loans at attractive terms to finance sustainability investments provided by Bregal’s dedicated EUR 40 million Sustainable Development Fund and, in 2020, with grants for charitable projects to contribute to portfolio companies’ pandemic responses provided by Bregal’s EUR 3 million COVID-19 relief fund. Furthermore, in 2021, BU committed to ambitious science-based climate targets for 2030 as part of its commitment to decarbonize its portfolio and achieve net-zero.